# Rhythm Pharmaceuticals Inc. (RYTM)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $5.70B  
**Price:** $87.66 (+2.28%)

> Rhythm Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases, particularly those involving hyperphagia and severe obesity. Its lead product, IMCIVREE (setmelanotide), is a precision medicine targeting rare melanocortin-4 receptor (MC4R) diseases, such as POMC deficiency and Bardet-Biedl syndrome, where traditional weight-loss treatments often prove ineffective. The company addresses unmet needs in rare disease obesity, a niche insulated from broader market dynamics in weight management drugs. Rhythm Pharmaceuticals Inc. operates in the pharmaceuticals and biotech sector, emphasizing treatments for genetic disorders that cause uncontrollable hunger and related complications. Headquartered in Boston, Massachusetts, and founded in 2008, it serves patients through specialized healthcare channels, positioning itself as a leader in rare disease therapies within the neuroendocrine space.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $190M | $170M | -$192M | -$197M | — |
| 2024 | $130M | $117M | -$266M | -$261M | — |
| 2023 | $77M | $68M | -$184M | -$185M | — |
| 2022 | $24M | $22M | -$179M | -$181M | — |
| 2021 | $3M | $3M | -$170M | -$70M | — |
| 2020 | — | — | -$137M | -$134M | — |
| 2019 | — | — | -$146M | -$141M | — |
| 2018 | — | — | -$78M | -$74M | — |
| 2017 | — | — | -$32M | -$34M | — |
| 2016 | — | — | -$26M | — | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $480M | $210M | $139M | $54M | $101M |
| 2024 | $392M | $228M | $22M | $89M | $108M |
| 2023 | $333M | $163M | $170M | $60M | $106M |
| 2022 | $382M | $118M | $264M | $128M | — |
| 2021 | $330M | $45M | $284M | $59M | — |
| 2020 | $187M | $21M | $167M | $101M | — |
| 2019 | $309M | $28M | $281M | $62M | — |
| 2018 | $260M | $14M | $246M | $50M | — |
| 2017 | $152M | $7M | $145M | $34M | — |
| 2016 | $12M | $5M | -$33M | $7M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$116M | $953,000 | -$117M |
| 2024 | -$114M | — | -$114M |
| 2023 | -$136M | $47,000 | -$136M |
| 2022 | -$173M | $281,000 | -$174M |
| 2021 | -$146M | $434,000 | -$146M |
| 2020 | -$122M | $214,000 | -$122M |
| 2019 | -$123M | $3M | -$126M |
| 2018 | -$62M | $722,000 | -$63M |
| 2017 | -$29M | $133,000 | -$30M |
| 2016 | -$23M | $1M | -$24M |
| 2015 | -$7M | $17,000 | -$7M |

Source: [CompaniesByCap](https://companiesbycap.com/company/RYTM)